An observational study from Washington University in St. Louis has shed more light on the benefits—as well as the risks—of using new diabetes and weight loss drugs from Novo Nordisk and Eli Lilly. According to the study, researchers found that use of the new medicines may reduce the risk of Alzheimer’s disease and substance abuse disorders while increasing the risk of digestive issues and arthritis.

AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate, TROP2-directed Dato-Dxd, has crossed the U.S. regulatory finish line.

“There's an evolution of our economic model that starts with IRA, and will get worse and worse and worse, but I think there's so many opportunities for us to counter that with new ways of working,” R&D head Andy Plump, M.D., Ph.D., told Fierce Biotech at the annual J.P. Morgan Healthcare Conference.

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase eightfold in a decade as therapies address unmet medical need.

A new study of nerve cells affected by Huntington’s disease reveals that the disease-causing gene slowly expands over time but doesn't start causing harm until it hits a toxic threshold that rapidly leads to the nerve cell’s death.